Inflammatory Tumour Cell Killing by Oncolytic Reovirus for the Treatment of Melanoma

Overview

Journal Gene Ther

Date 2008 Apr 11

PMID 18401435

Citations 66

Authors

F Errington

C L White

K R Twigger

A Rose

K Scott

L Steele

L J Ilett

R Prestwich

H S Pandha

M Coffey

P Selby

R Vile

K J Harrington

A A Melcher

Affiliations

Soon will be listed here.

Abstract

Reovirus is a promising unmodified double-stranded RNA (dsRNA) anti-cancer oncolytic virus, which is thought to specifically target cells with activated Ras. Although reovirus has been tested in a wide range of preclinical models and has entered early clinical trials, it has not previously been tested for the treatment of human melanoma. Here, we show that reovirus effectively kills and replicates in both human melanoma cell lines and freshly resected tumour; intratumoural injection also causes regression of melanoma in a xenograft in vivo model. Reovirus-induced melanoma death is blocked by caspase inhibition and is dependent on constituents of the Ras/RalGEF/p38 pathway. Reovirus melanoma killing is more potent than, and distinct from, chemotherapy or radiotherapy-induced cell death; a range of inflammatory cytokines and chemokines are released by infected tumour cells, while IL-10 secretion is abrogated. Furthermore, the inflammatory response generated by reovirus-infected tumour cells causes bystander toxicity against reovirus-resistant tumour cells and activates human myeloid dendritic cells (DC) in vitro. Hence, reovirus is suitable for clinical testing in melanoma, and may provide a useful danger signal to reverse the immunologically suppressive environment characteristic of this tumour.

Citing Articles

Advances in Cell and Immune Therapies for Melanoma.

Timis T, Buruiana S, Dima D, Nistor M, Muresan X, Cenariu D Biomedicines. 2025; 13(1).

PMID: 39857682 PMC: 11761552. DOI: 10.3390/biomedicines13010098.

Cytocidal Effect of Irradiation on Gastric Cancer Cells Infected with a Recombinant Mammalian Orthoreovirus Expressing a Membrane-Targeted KillerRed.

Shirasaka Y, Yamada K, Etoh T, Noguchi K, Hasegawa T, Ogawa K Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256912 PMC: 10818543. DOI: 10.3390/ph17010079.

Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis.

Xie R, Huang H, Chen T, Huang X, Chen C Front Pharmacol. 2023; 14:1228225.

PMID: 37829303 PMC: 10566296. DOI: 10.3389/fphar.2023.1228225.

Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.

Wang M, Wang X, Jin X, Zhou J, Zhang Y, Yang Y Front Immunol. 2023; 14:1175118.

PMID: 37304305 PMC: 10248152. DOI: 10.3389/fimmu.2023.1175118.

Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.

Holmes M, Scott G, Heaton S, Barr T, Askar B, Muller L Mol Ther Oncolytics. 2023; 29:17-29.

PMID: 37077714 PMC: 10106520. DOI: 10.1016/j.omto.2023.03.002.

References

Steele T, Cox D . Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine. Cancer Biother. 1995; 10(4):307-15. DOI: 10.1089/cbr.1995.10.307. View

Tyler K, Squier M, Rodgers S, Schneider B, Oberhaus S, Grdina T . Differences in the capacity of reovirus strains to induce apoptosis are determined by the viral attachment protein sigma 1. J Virol. 1995; 69(11):6972-9. PMC: 189616. DOI: 10.1128/JVI.69.11.6972-6979.1995. View

Alain T, Hirasawa K, Pon K, Nishikawa S, Urbanski S, Auer Y . Reovirus therapy of lymphoid malignancies. Blood. 2002; 100(12):4146-53. DOI: 10.1182/blood-2002-02-0503. View

Coffey M, Strong J, Forsyth P, Lee P . Reovirus therapy of tumors with activated Ras pathway. Science. 1998; 282(5392):1332-4. DOI: 10.1126/science.282.5392.1332. View

Schuler G, Schuler-Thurner B, Steinman R . The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003; 15(2):138-47. DOI: 10.1016/s0952-7915(03)00015-3. View

Strong J, Lee P . The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol. 1996; 70(1):612-6. PMC: 189854. DOI: 10.1128/JVI.70.1.612-616.1996. View

Ikeda Y, Nishimura G, Yanoma S, Kubota A, Furukawa M, Tsukuda M . Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx. 2004; 31(4):407-12. DOI: 10.1016/j.anl.2004.07.003. View

Selb B, Weber B . A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods. 1994; 47(1-2):15-25. DOI: 10.1016/0166-0934(94)90062-0. View

Schulz O, Diebold S, Chen M, Naslund T, Nolte M, Alexopoulou L . Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature. 2005; 433(7028):887-92. DOI: 10.1038/nature03326. View

10.

Alain T, Kim T, Lun X, Liacini A, Schiff L, Senger D . Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther. 2007; 15(8):1512-21. PMC: 7185731. DOI: 10.1038/sj.mt.6300207. View

11.

Norman K, Hirasawa K, Yang A, Shields M, Lee P . Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A. 2004; 101(30):11099-104. PMC: 503746. DOI: 10.1073/pnas.0404310101. View

12.

Kedl R, Rees W, Hildeman D, Schaefer B, Mitchell T, Kappler J . T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med. 2000; 192(8):1105-13. PMC: 2195874. DOI: 10.1084/jem.192.8.1105. View

13.

Lee P, Hayes E, Joklik W . Characterization of anti-reovirus immunoglobulins secreted by cloned hybridoma cell lines. Virology. 1981; 108(1):134-46. DOI: 10.1016/0042-6822(81)90533-x. View

14.

Sanchez-Perez L, Kottke T, Daniels G, Diaz R, Thompson J, Pulido J . Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol. 2006; 177(6):4168-77. DOI: 10.4049/jimmunol.177.6.4168. View

15.

Marcato P, Shmulevitz M, Lee P . Connecting reovirus oncolysis and Ras signaling. Cell Cycle. 2005; 4(4):556-9. DOI: 10.4161/cc.4.4.1600. View

16.

Kasper B, DHondt V, Vereecken P, Awada A . Novel treatment strategies for malignant melanoma: a new beginning?. Crit Rev Oncol Hematol. 2007; 62(1):16-22. DOI: 10.1016/j.critrevonc.2006.11.007. View

17.

Smakman N, van den Wollenberg D, Borel Rinkes I, Hoeben R, Kranenburg O . Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol. 2005; 79(23):14981-5. PMC: 1287595. DOI: 10.1128/JVI.79.23.14981-14985.2005. View

18.

Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee P . Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther. 2007; 15(8):1522-30. DOI: 10.1038/sj.mt.6300179. View

19.

Moser B, Wolf M, Walz A, Loetscher P . Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004; 25(2):75-84. DOI: 10.1016/j.it.2003.12.005. View

20.

Araki S, Omori Y, Lyn D, Singh R, Meinbach D, Sandman Y . Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007; 67(14):6854-62. DOI: 10.1158/0008-5472.CAN-07-1162. View